4//SEC Filing
Doerfler Douglas 4
Accession 0001209191-23-057093
CIK 0001287098other
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 5:14 PM ET
Size
14.8 KB
Accession
0001209191-23-057093
Insider Transaction Report
Form 4
MAXCYTE, INC.MXCT
Doerfler Douglas
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-11-29$5.00/sh−5,350$26,750→ 333,197 total - Exercise/Conversion
Common Stock
2023-12-01$0.04/sh+20,200$808→ 353,397 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-11-29−5,350→ 229,730 totalExercise: $0.04Exp: 2024-11-11→ Common Stock (5,350 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2023-12-01−20,200→ 209,530 totalExercise: $0.04Exp: 2024-11-11→ Common Stock (20,200 underlying) - Exercise/Conversion
Common Stock
2023-11-29$0.04/sh+5,350$214→ 338,547 total - Sale
Common Stock
2023-12-01$5.00/sh−20,200$101,000→ 333,197 total
Footnotes (3)
- [F1]The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option is fully vested and exercisable.
Documents
Issuer
MAXCYTE, INC.
CIK 0001287098
Entity typeother
Related Parties
1- filerCIK 0001874482
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 5:14 PM ET
- Size
- 14.8 KB